Pipeline
Ethris’ wholly owned pipeline comprises first- or best-in-class mRNA-based product candidates for treatment of asthma and rare pulmonary diseases. The versatility of our technology platform enables us to address an array of diverse diseases with unmet medical needs.
Indications
Asthma and COPD
Uncontrolled asthma is a significant burden for patients as ~50% of moderate and severe asthma patients are classified as uncontrolled despite current medication. In the US these are 4.4M patients suffering from asthma attacks leading to 1 million annual emergency department visits & 100 thousand inpatient stays.
Since 80% of acute asthma attacks are associated with virus infections, Ethris develops ETH47 as a first-in class therapy correcting low interferon lambda levels in asthmatics to prevent asthma attacks driven by viruses.
Mucosal Vaccines
Vaccines that directly target the entry site of respiratory viruses can elicit mucosal immunity and are more likely to prevent infection and interrupt transmission than conventional intramuscular shots.
Based on our SNAP LNP® technology, Ethris is developing a spray-dried mucosal RNA vaccine platform that is stable at room temperature and capable of generating a localized immune response.
Protein Replacement Therapies
Primary Ciliary Dyskinesia (PCD) is a rare disease that arises from structural defects or the absence of the cilia lining our respiratory tract. With the cilia unable to function, mucus loaded with trapped microbes, dust, and other debris cannot be cleared from the airways efficiently and can often lead to permanent lung damage. With our SNIM®RNA technology we can deliver a corrected mRNA that is designed to produce ciliary proteins in the respiratory tract thereby reconstituting cilia function.
Strategic Resilience and Biodefense
Across all programs, Ethris is aligned around a unifying strategic imperative: strengthening preparedness against respiratory viral threats and building long‑term resilience for public health systems. By targeting vulnerable patient populations and critical personnel, we aim to reduce the burden of virus‑induced exacerbations, hospitalizations, and transmission chains.
In-house developed mRNA technologies, European manufacturing partnerships and SNaP LNP®‑enabled, inhaled or intranasal delivery provide a rapid, scalable response infrastructure for emerging pathogens. This positions Ethris as a key enabler of strategic biodefense.
Pipeline Progress
